| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-5491.2007.02365.X |
| P698 | PubMed publication ID | 18307459 |
| P50 | author | Stefano Del Prato | Q41467287 |
| P2093 | author name string | S Costa | |
| G Lepore | |||
| A Tiengo | |||
| R Trevisan | |||
| A Maran | |||
| D Bruttomesso | |||
| M Aragona | |||
| A Girelli | |||
| A Baritussio | |||
| U Valentini | |||
| E Iori | |||
| A Buhr | |||
| M Dal Pos | |||
| D Crazzolara | |||
| P2860 | cites work | Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes | Q46955572 |
| Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump | Q48001064 | ||
| Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. | Q51500191 | ||
| Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. | Q51728319 | ||
| Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. | Q55034466 | ||
| Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. | Q55041812 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Evaluation of a new measure of blood glucose variability in diabetes | Q30441973 | ||
| Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials | Q34010466 | ||
| Insulin pump therapy: a meta-analysis | Q35094023 | ||
| Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness | Q35767678 | ||
| Postprandial hyperglycemia and diabetes complications: is it time to treat? | Q35992276 | ||
| Crossover trials, degrees of freedom, the carryover problem and its dual | Q41943667 | ||
| Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. | Q43869414 | ||
| Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment | Q44381448 | ||
| Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. | Q44816722 | ||
| A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine | Q44953969 | ||
| Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. | Q45124449 | ||
| Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. | Q45285681 | ||
| Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. | Q46818826 | ||
| Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability | Q46876719 | ||
| Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial | Q46909176 | ||
| P433 | issue | 3 | |
| P921 | main subject | glucose | Q37525 |
| insulin glargine | Q417317 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 326-332 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine | |
| P478 | volume | 25 |
| Q55162068 | A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. |
| Q91633023 | Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study |
| Q42599377 | Assessment of glycemic variability in continuous subcutaneous insulin infusion therapy in type 1 diabetes related to anthropometry and complication status |
| Q37421693 | Average daily risk range as a measure for clinical research and routine care |
| Q38081905 | Biological variation of cardiovascular risk factors in patients with diabetes. |
| Q37492413 | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| Q34296834 | Clinical Experience with Insulin Glargine in Type 1 Diabetes |
| Q37235857 | Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. |
| Q34119580 | Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes |
| Q42599701 | Computing the risk of postprandial hypo- and hyperglycemia in type 1 diabetes mellitus considering intrapatient variability and other sources of uncertainty |
| Q34449270 | Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis. |
| Q33403231 | Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy |
| Q24240609 | Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus |
| Q53489843 | Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. |
| Q36091280 | Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis |
| Q37384180 | Dynamic Stress Factor (DySF): A Significant Predictor of Severe Hypoglycemic Events in Children with Type 1 Diabetes |
| Q37972352 | External insulin pump treatment in the day-to-day management of diabetes: benefits and future prospectives |
| Q37022673 | Glucose variability assessed by low blood glucose index is predictive of hypoglycemic events in patients with type 1 diabetes switched to pump therapy. |
| Q42100765 | Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: an exploratory study. |
| Q36328989 | Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technology--New Possibility to Decrease Cardiovascular Risk? |
| Q42545434 | Improved quality of life in unselected insulin pump-treated children with type 1 diabetes in Eastern Nebraska |
| Q37437141 | Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study |
| Q47348006 | Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy |
| Q37358869 | Insulin therapy with personal insulin pumps and early angiopathy in children with type 1 diabetes mellitus. |
| Q37988797 | Management of diabetes mellitus: is the pump mightier than the pen? |
| Q85618582 | Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study |
| Q30409804 | The evidence base for diabetes technology: appropriate and inappropriate meta-analysis |
| Q50123365 | The process of incorporating insulin pumps into the everyday lives of people with Type 1 diabetes: A critical interpretive synthesis. |
| Q40571655 | Translating glucose variability metrics into the clinic via Continuous Glucose Monitoring: a Graphical User Interface for Diabetes Evaluation (CGM-GUIDE©). |
| Q86062721 | Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI |
| Q38085657 | Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review |
| Q49168090 | Vascular function and glucose variability improve transiently following initiation of continuous subcutaneous insulin infusion in children with type 1 diabetes |
Search more.